Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 28, 2003. The report serves as a notification of changes in director interests regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within the GlaxoSmithKline US Retirement Savings Plan.
Material Changes
- Retirement Plan Holdings: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,566,503 to 18,526,074.
- Transaction Details: The reduction occurred on April 24, 2003, due to fund movements, with an average price of $39.58 per share.
- Director Interest: Dr. J P Garnier, a company director, is noted as potentially interested in the shares held within this discretionary fund, similar to other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosed change in director interests.
Key Facts for Investor Verification
- Verify the impact of the ADR reduction on the total share count and potential dilution or concentration effects.
- Confirm the specific nature of Dr. J P Garnier's interest in the discretionary fund versus direct ownership.
- Review the full annual report (Form 20-F) for comprehensive financial performance data, as this 6-K is limited to director interest disclosures.